Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Quantum Biopharma ( (TSE:QNTM) ).
On November 25, 2025, Quantum BioPharma announced that CTV News’ investigative program W5 will feature a three-part series on the company’s $700 million lawsuit against CIBC and RBC for alleged stock market manipulation. The series, starting today, highlights the illegal practice of ‘stock spoofing’ and its potential impact on Quantum BioPharma’s multiple sclerosis research. The company aims to raise awareness of such manipulative practices and their effects on stakeholders, while continuing to focus on the development of its promising drug, Lucid-MS.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative, metabolic, and alcohol misuse disorders. The company, through its subsidiary Lucid Psycheceuticals Inc., is advancing its lead compound Lucid-MS, which has shown promise in preclinical models for treating multiple sclerosis. Quantum BioPharma also maintains strategic investments and holds a stake in Unbuzzd Wellness Inc., a company offering an OTC version of its product unbuzzd.
Average Trading Volume: 2,886
Technical Sentiment Signal: Sell
Current Market Cap: C$34.35M
For detailed information about QNTM stock, go to TipRanks’ Stock Analysis page.